A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.
Smac mimetic
gynecologic malignancies
relapsed/refractory disease
small cell lung cancer
topotecan
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 07 2023
05 07 2023
Historique:
received:
05
01
2023
accepted:
18
01
2023
medline:
7
7
2023
pubmed:
2
5
2023
entrez:
2
5
2023
Statut:
ppublish
Résumé
This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer (SCLC) and select gynecological cancers. Cohorts of 3-6 patients initiated treatment with LCL161 and topotecan in escalating doses. LCL161 was administered orally on days 1, 8, and 15 of each 21-day cycle; topotecan was administered orally for the first 5 days of each 21-day cycle. A total of 35 patients were enrolled in 6 cohorts; 30 patients were female; 4 patients had SCLC and 19 patients had ovarian cancer. Median prior lines of therapy were 3 (1-10). Median duration of treatment was 7.1 weeks (0.1-174). The most frequent grade 3/4 treatment-related adverse events were thrombocytopenia (51.43%) and anemia (31.43%). ORR was 9.7%; 58% of patients had SD. The study was stopped early before the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) were determined. The addition of LCL161 to oral topotecan caused more myelosuppression when dosed together than what was associated with either drug alone. Moreover, the drug combination did not improve outcomes. The study was terminated early (ClinicalTrials.gov Identifier: NCT02649673).
Sections du résumé
BACKGROUND
This was an open-label, multicenter, single-arm phase Ib dose-escalation study of oral LCL161 administered in combination with oral topotecan in patients with relapsed/refractory small cell lung cancer (SCLC) and select gynecological cancers.
METHODS
Cohorts of 3-6 patients initiated treatment with LCL161 and topotecan in escalating doses. LCL161 was administered orally on days 1, 8, and 15 of each 21-day cycle; topotecan was administered orally for the first 5 days of each 21-day cycle.
RESULTS
A total of 35 patients were enrolled in 6 cohorts; 30 patients were female; 4 patients had SCLC and 19 patients had ovarian cancer. Median prior lines of therapy were 3 (1-10). Median duration of treatment was 7.1 weeks (0.1-174). The most frequent grade 3/4 treatment-related adverse events were thrombocytopenia (51.43%) and anemia (31.43%). ORR was 9.7%; 58% of patients had SD. The study was stopped early before the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) were determined.
CONCLUSION
The addition of LCL161 to oral topotecan caused more myelosuppression when dosed together than what was associated with either drug alone. Moreover, the drug combination did not improve outcomes. The study was terminated early (ClinicalTrials.gov Identifier: NCT02649673).
Identifiants
pubmed: 37129455
pii: 7147832
doi: 10.1093/oncolo/oyad029
pmc: PMC10322128
doi:
Substances chimiques
Topotecan
7M7YKX2N15
LCL161
0
Banques de données
ClinicalTrials.gov
['NCT02649673']
Types de publication
Clinical Trial, Phase I
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
640-e559Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
J Clin Oncol. 1998 Oct;16(10):3345-52
pubmed: 9779711
Gynecol Oncol. 1997 Sep;66(3):480-6
pubmed: 9299264
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11936-41
pubmed: 20547836
Cancer Lett. 2014 Sep 1;351(2):232-41
pubmed: 24976294
J Clin Oncol. 2014 Oct 1;32(28):3103-10
pubmed: 25113756
Leukemia. 2010 Dec;24(12):2100-9
pubmed: 20844561
J Clin Oncol. 1997 May;15(5):2090-6
pubmed: 9164222
Oncotarget. 2016 Nov 8;7(45):72634-72653
pubmed: 27655666
J Exp Clin Cancer Res. 2016 Sep 30;35(1):158
pubmed: 27737687
J Clin Oncol. 2000 Mar;18(5):1062-7
pubmed: 10694558
J Clin Oncol. 2006 May 1;24(13):2044-51
pubmed: 16648504